91 related articles for article (PubMed ID: 29080385)
1. Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.
Bandyopadhyay A; Favours E; Phelps DA; Pozo VD; Ghilu S; Kurmashev D; Michalek J; Trevino A; Guttridge D; London C; Hirotani K; Zhang L; Kurmasheva RT; Houghton PJ
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29080385
[TBL] [Abstract][Full Text] [Related]
2. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
Morton CL; Maris JM; Keir ST; Gorlick R; Kolb EA; Billups CA; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2012 Apr; 58(4):566-71. PubMed ID: 21538824
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.
Malempati S; Weigel B; Ingle AM; Ahern CH; Carroll JM; Roberts CT; Reid JM; Schmechel S; Voss SD; Cho SY; Chen HX; Krailo MD; Adamson PC; Blaney SM
J Clin Oncol; 2012 Jan; 30(3):256-62. PubMed ID: 22184397
[TBL] [Abstract][Full Text] [Related]
4. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Kurmashev D; Reynolds CP; Kang M; Wu J; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921800
[TBL] [Abstract][Full Text] [Related]
5. Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma.
Kang Z; Goldstein SD; Yu Y; Meltzer PS; Loeb DM; Cao L
Br J Cancer; 2015 Sep; 113(6):894-901. PubMed ID: 26291055
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and mechanical properties of chemotherapy-impregnated cement in Ewing sarcoma.
Goldin AN; Healey RM
J Orthop Res; 2023 Nov; 41(11):2540-2546. PubMed ID: 36971130
[TBL] [Abstract][Full Text] [Related]
7. ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies.
Hollingshead MG; Greenberg N; Gottholm-Ahalt M; Camalier R; Johnson BC; Collins JM; Doroshow JH
Cancer Res; 2022 Jun; 82(12):2219-2225. PubMed ID: 35472132
[TBL] [Abstract][Full Text] [Related]
8. Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience.
Nikanjam M; Wing J; Capparelli E; Kurzrock R
Cureus; 2018 Nov; 10(11):e3634. PubMed ID: 30705793
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation.
Geier B; Kurmashev D; Kurmasheva RT; Houghton PJ
Front Oncol; 2015; 5():193. PubMed ID: 26380223
[TBL] [Abstract][Full Text] [Related]
10. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.
Johnson KM; Taslim C; Saund RS; Lessnick SL
PLoS One; 2017; 12(11):e0186275. PubMed ID: 29091716
[TBL] [Abstract][Full Text] [Related]
11. EWS-FLI-1 creates a cell surface microenvironment conducive to IGF signaling by inducing pappalysin-1.
Jayabal P; Houghton PJ; Shiio Y
Genes Cancer; 2017 Nov; 8(11-12):762-770. PubMed ID: 29321818
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial.
von Einem JC; Peter S; Günther C; Volk HD; Grütz G; Salat C; Stoetzer O; Nelson PJ; Michl M; Modest DP; Holch JW; Angele M; Bruns C; Niess H; Heinemann V
Oncotarget; 2017 Oct; 8(46):80156-80166. PubMed ID: 29113291
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma.
Hayashi M; Baker A; Goldstein SD; Albert CM; Jackson KW; McCarty G; Kahlert UD; Loeb DM
Oncotarget; 2017 Oct; 8(45):78265-78276. PubMed ID: 29108227
[TBL] [Abstract][Full Text] [Related]
14. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
Lin GHY; Chai V; Lee V; Dodge K; Truong T; Wong M; Johnson LD; Linderoth E; Pang X; Winston J; Petrova PS; Uger RA; Viller NN
PLoS One; 2017; 12(10):e0187262. PubMed ID: 29084248
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and pharmacokinetics of tazemetostat.
Orleni M; Beumer JH
Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
[TBL] [Abstract][Full Text] [Related]
16. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.
Candido MF; Medeiros M; Veronez LC; Bastos D; Oliveira KL; Pezuk JA; Valera ET; Brassesco MS
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839989
[TBL] [Abstract][Full Text] [Related]
17. HER3 in cancer: from the bench to the bedside.
Gandullo-Sánchez L; Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2022 Oct; 41(1):310. PubMed ID: 36271429
[TBL] [Abstract][Full Text] [Related]
18. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.
Gao J; Pickett HA
Nat Rev Cancer; 2022 Sep; 22(9):515-532. PubMed ID: 35790854
[TBL] [Abstract][Full Text] [Related]
19. HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy.
De Giovanni C; Landuzzi L; Palladini A; Nicoletti G; Nanni P; Lollini PL
Cells; 2021 Jul; 10(7):. PubMed ID: 34359977
[TBL] [Abstract][Full Text] [Related]
20. Analysis of drug sensitivity of human high-grade osteosarcoma in a chick chorioallantoic membrane (CAM) model: a proof of principle study.
Guder WK; Hartmann W; Trautmann M; Hardes J; Wardelmann E; Balke M; Streitbürger A
BMC Res Notes; 2020 Sep; 13(1):432. PubMed ID: 32933563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
